Santafe News Online

Open Angle Glaucoma Pipeline

According to DelveInsight’s analysis, the global Open-Angle Glaucoma pipeline includes more than 18 active companies developing over 20 therapeutic candidates. The assessment covers clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and key developmental progress.

The “Open Angle Glaucoma Pipeline Insight, 2025” report provides a comprehensive overview of the current clinical landscape and future growth potential within the Open-Angle Glaucoma market.

This pipeline report offers a thorough commercial and clinical evaluation of drug candidates from preclinical stages through marketed therapies. It also presents detailed profiles of each product, including mechanisms of action, clinical trial data, regulatory milestones, and ongoing development activities such as technological advancements, partnerships, mergers and acquisitions, funding initiatives, and special designations.

Request for Sample Report here @ Open Angle Glaucoma Pipeline Outlook

Some of the key takeaways from the Open Angle Glaucoma Pipeline Report:

• Open Angle Glaucoma Companies across the globe are diligently working toward developing novel Open Angle Glaucoma treatment therapies with a considerable amount of success over the years.
• Open Angle Glaucoma companies working in the treatment market are Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS and others, are developing therapies for the Open Angle Glaucoma treatment
• Emerging Open Angle Glaucoma therapies such as TO-O-1001, BTQ-1902, NCX 470, and others are expected to have a significant impact on the Open Angle Glaucoma market in the coming years.
• In April 2025, Perfuse Therapeutics, Inc announced results of a phase 1/2a Study to Evaluate Safety, Tolerability, and Pharmacodynamic Effect After Single Administration of PER-001 Intravitreal Implant in Participants With Open-Angle Glaucoma
• In March 2025, Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a global ophthalmology company, announced that the final patient has completed their last visit in the Whistler Phase 3b trial evaluating NCX 470’s dual mechanism of action – nitric oxide and prostaglandin analog – for reducing intraocular pressure (IOP). NCX 470, Nicox’s lead clinical candidate, is an innovative NO-donating bimatoprost eye drop currently in Phase 3 development for treating open-angle glaucoma and ocular hypertension.
• In February 2025, Qlaris Bio, Inc., a clinical-stage biotechnology company focused on addressing unmet needs in severe ophthalmic conditions, has reported positive topline results from two U.S. Phase II trials evaluating QLS-111 in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). The Phase II studies, Osprey and Apteryx, achieved all primary and secondary endpoints successfully.
• In January 2025, Glaukos Corporation (NYSE: GKOS), a company specializing in ophthalmic pharmaceuticals and medical technologies for glaucoma treatment, has launched a Phase 2b/3 clinical program for iDose TREX, its next-generation sustained-release therapeutic platform. iDose TREX is designed to resemble the original iDose TR in size and shape but offers nearly double the drug capacity.
• In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference in Chicago, Illinois, findings from a Phase II study on the safety of Neurotech Pharmaceuticals’ NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The study focused on neuroprotection in patients with glaucoma. Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University, shared the results, which demonstrated that CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported.
• In March 2024, MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.
• In February 2024, Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
• ASCRS 2024: Phase 2 trial of travoprost intracameral implant in open-angle glaucoma or ocular hypertension

Open Angle Glaucoma Overview

Open-angle glaucoma is the most common form of glaucoma, characterized by progressive optic nerve damage caused by increased resistance to aqueous humor outflow through the trabecular meshwork. The condition develops slowly and often without noticeable symptoms until significant vision loss occurs, making early detection critical. Risk factors include aging, family history, elevated intraocular pressure (IOP), and comorbidities such as diabetes or hypertension. Diagnosis typically involves optic nerve examination, visual field testing, and tonometry. Management focuses on reducing IOP through medications, laser therapy, or surgical procedures to prevent further optic nerve damage and preserve long-term visual function.

Get a Free Sample PDF Report to know more about Open Angle Glaucoma Pipeline Therapeutic Assessment- Open Angle Glaucoma Treatment Market

Open Angle Glaucoma Route of Administration

Open Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Open Angle Glaucoma Molecule Type

Open Angle Glaucoma Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

Open Angle Glaucoma Pipeline Therapeutics Assessment

• Open Angle Glaucoma Assessment by Product Type
• Open Angle Glaucoma By Stage and Product Type
• Open Angle Glaucoma Assessment by Route of Administration
• Open Angle Glaucoma By Stage and Route of Administration
• Open Angle Glaucoma Assessment by Molecule Type
• Open Angle Glaucoma by Stage and Molecule Type

DelveInsight’s Open Angle Glaucoma Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Open Angle Glaucoma product details are provided in the report. Download the Open Angle Glaucoma pipeline report to learn more about the emerging Open Angle Glaucoma therapies- Open Angle Glaucoma Drugs and Therapies

Open Angle Glaucoma Pipeline Analysis:

The Open-Angle Glaucoma pipeline report offers comprehensive insights into:

• A detailed evaluation of the companies developing treatment options for Open-Angle Glaucoma, along with an overview of the number and type of therapies each company is advancing.
• An assessment of therapeutic candidates categorized by early-, mid-, and late-stage development.
• Key industry players engaged in targeted therapy development, including both active programs and inactive (discontinued or dormant) projects.
• A breakdown of pipeline drugs by development stage, route of administration, therapeutic target, monotherapy or combination use, mechanism of action, and molecular class.
• An in-depth review of collaborations – spanning industry partnerships, academic alliances, licensing deals, and funding activities – supporting future progress in the Open-Angle Glaucoma market.

Download Sample PDF Report to know more about Open Angle Glaucoma drugs and therapies- Open Angle Glaucoma Clinical Trials and FDA Approvals

Scope of Open Angle Glaucoma Pipeline Drug Insight

• Coverage: Global
• Key Open Angle Glaucoma Companies: Nicox Ophthalmics (EPA: COX), Betaliq, Inc. (Private), Qlaris Bio (Private), Aerpio Pharmaceuticals (OTC: ARPO), Theratocular Biotek (Private), PolyActiva Pty Ltd. (Private), Whitecap Biosciences (Private), JeniVision (Private), EMS (Private), and others
• Key Open Angle Glaucoma Therapies: TO-O-1001, BTQ-1902, NCX 470, and others.
• Open Angle Glaucoma Therapeutic Assessment: Open Angle Glaucoma current marketed and Open Angle Glaucoma emerging therapies
• Open Angle Glaucoma Market Dynamics: Open Angle Glaucoma market drivers and Open Angle Glaucoma market barriers

Request for Sample PDF Report for Open Angle Glaucoma Pipeline Assessment and clinical trials – Open Angle Glaucoma Therapeutics Market

Table of Contents

1. Open Angle Glaucoma Report Introduction

2. Open Angle Glaucoma Executive Summary

3. Open Angle Glaucoma Overview

4. Open Angle Glaucoma- Analytical Perspective In-depth Commercial Assessment

5. Open Angle Glaucoma Pipeline Therapeutics

6. Open Angle Glaucoma Late Stage Products (Phase II/III)

7. Open Angle Glaucoma Mid Stage Products (Phase II)

8. Open Angle Glaucoma Early Stage Products (Phase I)

9. Open Angle Glaucoma Preclinical Stage Products

10. Open Angle Glaucoma Therapeutics Assessment

11. Open Angle Glaucoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Open Angle Glaucoma Companies

14. Open Angle Glaucoma Key Products

15. Open Angle Glaucoma Unmet Needs

16 . Open Angle Glaucoma Market Drivers and Barriers

17. Open Angle Glaucoma Future Perspectives and Conclusion

18. Open Angle Glaucoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services